Why Obesity Drug Coverage Doesn’t Matter (Yet) for Lilly and Novo
Wall Street Journal
Makers of Wegovy, Ozempic and Zepbound can’t keep up with skyrocketing demand for their GLP-1 drugs, so insurance coverage isn’t important for near-term growth.
https://www.wsj.com/articles/why-obesity-drug-coverage-doesnt-matter-yet-for-lilly-and-novo-8bdcc8b7